Search
Benzonatate
go.drugbank.com/drugs/DB00868ApprovedBenzonatate was approved by the FDA in 1958 under the market name Tessalon Perles.
Dapagliflozin
go.drugbank.com/drugs/DB06292ApprovedInvestigational[A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise.
Products: Nra-dapagliflozinLinaclotide
go.drugbank.com/drugs/DB08890ApprovedInvestigationalLinaclotide was first approved by the FDA on August 30, 2012.[A260271] It gained EMA and Health Canada approval on November 26, 2012 [L47216] and December 3, 2013,[L47221] respectively.
Bexagliflozin
go.drugbank.com/drugs/DB12236ApprovedInvestigational[A256423,L44758] In January 2023, bexagliflozin was approved by the FDA for the treatment of adults with type 2 diabetes.
Chloroprocaine
go.drugbank.com/drugs/DB01161ApprovedInvestigational[A252952,L43382] Topical chloroprocaine for ophthalmic use was approved by the FDA in September 2022 for ocular surface anesthesia.[L43387]
Sevoflurane
go.drugbank.com/drugs/DB01236ApprovedInvestigationalVet approved[L42340] Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996.
Flavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on
Ursodeoxycholic acid
go.drugbank.com/drugs/DB01586ApprovedInvestigational[A256272] UDCA was first approved by the FDA in 1987 for dissolution of gallstones and for primary biliary cirrhosis in 1996.
Products: Nra-ursodiolVitamin A
go.drugbank.com/drugs/DB00162ApprovedInvestigationalNutraceuticalVet approvedRetinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A i...
Mixtures: PNV 27-Ca/Fe/FA, O-Cal FA multivitaminOtamixaban
go.drugbank.com/drugs/DB06635InvestigationalOtamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.